May Cho, M.D.

May Cho, M.D.

Specialties

Hematology/Oncology

Department

Internal Medicine

Title

  • Assistant Professor
To see if May Cho is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Philosophy of Care

Dr. Cho is an adult medical oncologist who specializes in medical treatment of gastrointestinal malignancies including esophageal, gastric,pancreatic, hepatobiliary, and colorectal cancers.

She is a strong advocate for providing patients with comprehensive care such as mutational profiling, regional therapies, clinical trials and supportive care.

Clinical Interests

Dr. Cho is an adult medical oncologist who specializes in medical treatment of gastrointestinal malignancies including esophageal, gastric,pancreatic, hepatobiliary, and colorectal cancers.

Research/Academic Interests

Dr Cho is interested in conducting clinical trials for these malignancies and has a particular interest in novel treatments for colorectal cancer including molecular targeted therapies, immunotherapies and liver directed therapies.

Division

Hematology and Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Education

M.D., Meharry Medical College, Nashville TN 2011

B.A., UC Berkeley, Berkeley CA 2005

Residency

Internal Medicine, Banes-Jewish Hospital, St. Louis MO 2012-2014

Fellowships

Hematology and Oncology, City of Hope/Harbor-UCLA, Duarte CA 2014-2017

Board Certifications

American Board of Internal Medicine, 2014

Professional Memberships

American Society of Clinical Oncology

Honors and Awards

Conquer Cancer Foundation of ASCO Merit Award, Gastrointestinal Cancer Symposium, San Francisco, 2016

City of Hope Clinical Investigation Training Program Scholar (one year curriculum), 2015

Mentor in Medicine research award, Washington University, St. Louis, 2012

Alpha Omega Alpha Medical Honor Society, 2010

Select Recent Publications

Gong J, Cho M, Sy M, Salgia R, Fakih M. Molecular profiling of metastatic colorectal tumors using next-generation sequencing: A single-institution experience. Oncotarget. 2017 Feb 2. [Epub ahead of print]

Gong J, Cho M, Fakih M. RAS and BRAF in metastatic colorectal cancer management. J Gastrointest Oncol. 2016 Oct;7(5):687-704.

Cho M, Akiba C, Lau C, Smith D, Telatar M, Afkhami M, Sentovich S, Melstrom K, Fakih M. Impact of RAS and BRAF mutations on carcinoembryonic antigen production  and pattern of colorectal metastases. World J Gastrointest Oncol. 2016 Jan 15;8(1):128-35.

Cho M, Gong J, Fakih M. The state of regional therapy in the management of metastatic colorectal cancer to the liver. Expert Rev Anticancer Ther. 2016;16(2):229-45.

Cho M, Wang-Gillam A, Myerson R, Gao F, Strasberg S, Picus J, Sorscher S, Fournier C, Nagaraj G, Parikh P, Suresh R, Linehan D, Tan BR. A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma. HPB (Oxford). 2015 Jul;17(7):587-93.

Peddi PF, Cho M, Wang J, Gao F, Wang-Gillam A. Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma. J Gastrointest Oncol. 2013 Dec;4(4):370-3.

Cho M, Peddi PF, Ding K, Chen L, Thomas D, Wang J, Lockhart AC, Tan B, Wang-Gillam A. Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma. J Transl Med. 2013 Sep 8;11:206.

Cho M, Kabir SM, Dong Y, Lee E, Rice VM, Khabele D, Son DS. Aspirin Blocks EGF-stimulated Cell Viability in a COX-1 Dependent Manner in Ovarian Cancer Cells. J Cancer. 2013 Sep 27;4(8):671-8.

Dunn T, Cho M, Medeiros B, Logan A, Ungewickell A, Liedtke M. Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options. Hematology. 2012 Nov;17(6):325-8.